REFERENCES
1. Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett 2016;379:198-205.
2. Li Q, Chen C, Su J, et al. Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study. BMC Cancer 2022;22:329.
3. Zhang XF, Chakedis J, Bagante F, et al. Implications of intrahepatic cholangiocarcinoma etiology on recurrence and prognosis after curative-intent resection: a multi-institutional study. World J Surg 2018;42:849-57.
4. Wang Q, Li J, Lei Z, et al. Prognosis of intrahepatic cholangiocarcinomas with hbv infection is better than those with hepatolithiasis after R0 liver resection: a propensity score matching analysis. Ann Surg Oncol 2017;24:1579-87.
5. Amin MB. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. Eight edition. Chicago, IL: American Joint Committee on Cancer, Springer; 2017. xvii 1024.
6. Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB 2015;17:669-80.
7. Kubo S, Shinkawa H, Asaoka Y, et al. Liver cancer study group of Japan clinical practice guidelines for intrahepatic cholangiocarcinoma. Liver Cancer 2022;11:290-314.
8. Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 2010;46:1056-61.
9. Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol 2014;27:1163-73.
10. Wang XW, Thorgeirsson SS. The biological and clinical challenge of liver cancer heterogeneity. Hepat Oncol 2014;1:349-53.
11. Shen X, Zhao H, Jin X, et al. Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis. Hepatobiliary Surg Nutr 2021;10:749-65.
12. Bao F, Liu J, Chen H, Miao L, Xu Z, Zhang G. Diagnosis biomarkers of cholangiocarcinoma in human bile: an evidence-based study. Cancers 2022;14:3921.
13. Liu XF, Tang K, Sui LL, Xu G. Cholangiocarcinoma: present status and molecular aspects of diagnosis. Oncol Res 2014;22:177-83.
